Significant Agreements - Additional Information (Details) $ in Millions		1 Months Ended								12 Months Ended
	Jul. 31, 2020 USD ($)	Oct. 31, 2023 USD ($)	Aug. 31, 2023 USD ($)	Apr. 30, 2023 GBP (£)	Aug. 31, 2022 USD ($)	Jul. 31, 2022	Jan. 31, 2022 GBP (£)	Jun. 30, 2020 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2023 GBP (£)	Dec. 31, 2023 USD ($)
License Agreement | Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time option exercise fee | £							£ 250,000
Payments for achievement of specific development and regulatory approval events | £							£ 19,500,000
Milestone payments relating to first and second tumor histologies | £				£ 750,000
License Agreement | Amgen Clinical Trial Collaboration and Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Pay for external third-party cost percentage						50.00%
Maximum | License Agreement | Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent development and sales-based milestone payments									$ 29.0
Maximum | License Agreement | Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional payments for achievement of specific development and regulatory approval events | £										£ 18,750,000
Milestone payments of phase two relating to first and second tumor histologies | £										1,500,000
Milestone payments of phase three relating to first and second tumor histologies | £										£ 2,250,000
GSK Collaboration Agreement | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive											$ 13.0
GSK Collaboration Agreement | GSK | License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 100.0
Number of days of notice period for terminating agreement								90 days
Pol Theta Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment received for achievement of initial preclinical development milestone			$ 3.0		$ 3.0
Milestone payment received clinical evaluation			$ 7.0
Additional payment of development milestone to achieve											10.0
Pol Theta Program | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive								$ 485.0
Commercial milestone payment eligible to receive								$ 475.0
Development milestone payment eligible to receive											$ 465.0
WRN Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage								20.00%
Milestone payment received for achievement of initial preclinical development milestone		$ 3.0
Milestone payment received clinical evaluation		$ 3.0
Percentage of profit share								50.00%
WRN Program | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Commercial milestone payment eligible to receive								$ 475.0
Development milestone payment eligible to receive								$ 485.0
WRN Program | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage								80.00%